Clinical trial
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly…
NCT00477750 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00477750 |
|---|---|
| Title | Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma |
| Official title | Phase I/II Trial of Melphalan, Prednisone Plus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Stem Cell Transplant |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | lenalidomide, melphalan, prednisone |
| Enrollment | 33 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Aug 5, 2013 |
| First posted | May 24, 2007 |
| Last update posted | Oct 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: